Skip to main content

Advertisement

Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup

Fig. 2

Relationship between CSF sTREM2 and CSF neurodegenerative biomarker levels. Graphs show associations between CSF sTREM2 and CSF T-tau (a), P-tau (b) and Aβ42 (c) levels for control and dementia groups, and between CSF sTREM2 levels and CSF T-tau (d), P-tau (e) and Aβ42 (f) levels for the control group and dementia subgroups defined by CSF biomarker status (pathological subgroups). AD biomarker-negative dementia: CSF T-tau/Aβ42 ratio < 1.0; AD biomarker-positive dementia: CSF T-tau/Aβ42 ratio > 1.0. Lines are group regression lines adjusted for age and sex (controls) and age, sex and disease duration (overall dementia group and biomarker-defined dementia subgroups). See main text for individual β and P values for each association. Aβ42 β-Amyloid 1–42, AD Alzheimer’s disease, CSF Cerebrospinal fluid, P-tau tau phosphorylated at position threonine-181, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, T-tau Total tau

Back to article page